BMY · NYSE · STOCK
Bristol Myers Squibb (BMY) Stock Analysis
$67.30
52W $42.52 – $68.64
60/100
$136.88B
14.8
0.23
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is BMY Bullish or Bearish?
Bullish.
Innellis AI committee rates Bristol Myers Squibb (BMY) Buy with a composite score of 60/100
, based on 6 analysts with 67% agreement.
Last updated August 25, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +15.43 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -4.57 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 99.3% yoy. Risk Analyst remains cautious — high leverage (debt-to-equity 2.44) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- P/E of 14.2 is inexpensive for the broad market — Value
- ROE of 46.8% shows genuine earnings power backing the valuation — Value
- Dividend yield of 4.6% pays you to wait — Value
- EPS growing 99.3% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Price-to-book of 5.9x prices in significant intangible value — Value
- Debt-to-equity of 2.44 adds balance-sheet risk to the value case — Value
- High leverage (debt-to-equity 2.44) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 25, 2026
Overall Committee Score
60/100
Agreement
67%
Analysts
6
Conviction
Contested
Sector Rank
Top 40%
of 192 Healthcare peers
Value Analyst
neutral
55
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ P/E of 14.2 is inexpensive for the broad market
− Price-to-book of 5.9x prices in significant intangible value
Growth Analyst
bullish
72
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 99.3% YoY
Technical Analyst
bullish
69
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 2.44) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 69 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3063.01)
Investment Thesis Evolution
Committee score moved marginally from 59.6 to 59.6.
Comparing 2026-08-24 to 2026-08-25 (1 day apart).
Technical Analysis
RSI (14)
63.1
Neutral
MACD Histogram
0.021
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$65.95
Resistance
$67.14
Bollinger %B
0.94
Inside Bands
Price vs Moving Averages
EMA 9
$65.61
Above
EMA 21
$64.26
Above
EMA 50
$61.86
Above
EMA 200
$57.45
Above
Fundamental Analysis
Valuation
76
Growth
87
Profitability
93
Financial Health
45
Cash Flow
70
Valuation
P/E Ratio
14.8×
P/B Ratio
6.13×
PEG Ratio
0.18
Dividend Yield
3.75%
52W High
$68.64
52W Low
$42.52
Quality & Growth
ROE
3818.5%
ROA
783.5%
Gross Margin
7015.7%
Operating Margin
2826.6%
Revenue Growth YoY
—
Debt / Equity
1.93
AI Fundamental Assessment
P/E ratio of 14.8 (inexpensive relative to a 15-40x range); Price-to-book of 6.1x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 38.2%; Return on assets of 7.8%; Net margin of 18.9%; Gross margin of 70.2%; Current ratio of 1.53 (healthy short-term liquidity); Debt-to-equity of 1.93; Free cash flow per share is positive (5.60); Most recent quarter beat estimates by 27.2%; 5 consecutive earnings beats; EPS growth accelerating (+25.4% -> +29.1% QoQ); Average YoY EPS growth of 39.7%; Analyst estimates rising over recent quarters
Get the Full BMY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →